January 29, 2008
Bausch makes foray into presbyopic arena
Analysis of:
Bausch & Lomb announces acquisition of eyeonics | www.osnsupersite.com
This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Implications: With the recent trends of presbyopic correction , Bausch and Lomb has now entered the arena.
Analysis: Utilizing a completely different mechanism of action, and an improved IOL platform, the Crystalens now has the opportunity to take a significant portion of market share from Alcon and AMO.Many colleagues (and I myself) have stopped utilizing ReStor and ReZoom due tp their excess amount of glare and halo. Even with "neuroadaptation" and careful patient selection, I have had to explant several of these multi-focal lens implants from unhappy patients. Contrarily, not one of my Crystalens patients has experienced excess glare, halos or diminished night vision.Given Bausch's surgical division's marketing power, Crystalens may now get fair exposure to ophthalmologists as well as to the general public. The new 5.0 lens has better accomodative abilities than the prior model leading to a greater reading range and happier post-operative patients.
Analysis: Utilizing a completely different mechanism of action, and an improved IOL platform, the Crystalens now has the opportunity to take a significant portion of market share from Alcon and AMO.Many colleagues (and I myself) have stopped utilizing ReStor and ReZoom due tp their excess amount of glare and halo. Even with "neuroadaptation" and careful patient selection, I have had to explant several of these multi-focal lens implants from unhappy patients. Contrarily, not one of my Crystalens patients has experienced excess glare, halos or diminished night vision.Given Bausch's surgical division's marketing power, Crystalens may now get fair exposure to ophthalmologists as well as to the general public. The new 5.0 lens has better accomodative abilities than the prior model leading to a greater reading range and happier post-operative patients.
Report a Concern
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
FDA Alert: Hemorrhagic or Necrotizing Pancreatitis in Patients Taking Byetta
www.fda.gov
Healthways' Guidance Not So Healthy
www.forbes.com
Drug Makers’ Push Leads to Cancer Vaccines’ Fast Rise
www.nytimes.com
Hospital Death Rates Unveiled for First-Time Comparison
www.usatoday.com
Temozolomide And Thalidomide Combination Effective Against Malignant Melanoma Spread To CNS And White Blood Cell Count May Be Prognostic
www.medicalnewstoday.com
Dangers of Methadone Usage
August 28, 2008
Its all about the spin
August 21, 2008
Byetta sale will reduce after FAD alert
August 19, 2008
PCI numbers will not drop after Courage
August 19, 2008
Bad News (but not new news) for stents.
August 19, 2008

